Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Geron ( (GERN) ) has issued an announcement.
Geron Corporation is set to participate in the 43rd Annual J.P. Morgan Healthcare Conference to discuss its promising commercial launch of RYTELO in the U.S. market. The company has reported strong financial results for RYTELO, with significant revenue growth in the third and fourth quarters of 2024, and anticipates reaching profitability without additional financing. The company highlights the potential market expansion opportunities for RYTELO, which could be further enhanced by positive outcomes from ongoing clinical trials, potentially doubling its commercial opportunity.
More about Geron
Geron Corporation operates in the biotechnology industry, focusing on developing and commercializing innovative treatments for blood cancers. Their primary product, RYTELO (imetelstat), is a first-in-class telomerase inhibitor targeting lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.
YTD Price Performance: -11.94%
Average Trading Volume: 10,217,442
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.92B
Find detailed analytics on GERN stock on TipRanks’ Stock Analysis page.
